Big News: FDA is moving from MasterControl to ComplianceQuest.See Why
Talk to a SpecialistLoading…
Talk to a SpecialistTalk to a SpecialistBased on limited metadata without access to the full warning letter, this case involves Montgomery Women's Medical Center PC (operating as Montgomery Fertility Center), a biologics manufacturer or handler, which received an FDA warning letter on May 14, 2020. Without an available subject line, the specific nature of the violations cannot be determined from the metadata provided. The warning falls under FDA's biologics regulatory authority, which typically encompasses human cells, tissues, and cellular/tissue-based products (HCT/Ps) commonly used in fertility and reproductive medicine. A complete review of the full warning letter would be necessary to identify the specific compliance failures cited by the FDA.